U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

LX-7101

MORE DETAILS

  74B3C4ZT96

Status:
Investigational
Source:
NCT01528111: Phase 1/Phase 2 Interventional Completed Primary Open-angle Glaucoma
(2012)
Source URL:
https://clinicaltrials.gov/ct2/show/NCT01528111
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
LIM domain kinase 2
2
Rho-associated protein kinase 2
25
LIM domain kinase 1
2
Conditions:
Open-angle glaucoma
53
Ocular hypertension
52
LX-7101 (Lexicon Pharmaceuticals) was advanced to Phase-I clinical trials for treatment open-angle glaucoma or ocular hypertension. This drug is a potent inhibitor of LIM-kinase 2 (LIMK2) kinase and inhibits to less extent LIMK1 and Rho-associated protein kinase 2 (ROCK2).

LX-7101 HYDROCHLORIDE

MORE DETAILS

  S5G8WJ39X9

Status:
Investigational
Source:
NCT01528111: Phase 1/Phase 2 Interventional Completed Primary Open-angle Glaucoma
(2012)
Source URL:
https://clinicaltrials.gov/ct2/show/NCT01528111
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
LIM domain kinase 2
2
Rho-associated protein kinase 2
25
LIM domain kinase 1
2
Conditions:
Open-angle glaucoma
53
Ocular hypertension
52
LX-7101 (Lexicon Pharmaceuticals) was advanced to Phase-I clinical trials for treatment open-angle glaucoma or ocular hypertension. This drug is a potent inhibitor of LIM-kinase 2 (LIMK2) kinase and inhibits to less extent LIMK1 and Rho-associated protein kinase 2 (ROCK2).
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966